Cosmetic Compositions and Methods Comprising Rhodiola Rosea

ABSTRACT

A cosmetic composition comprising a UV-protective amount of at least one rosavin, preferably present in an extract of  Rhodiola rosea  in a cosmetically acceptable vehicle, and methods of use thereof, including preventing or reducing the signs of photoaging.

This application is a continuation of U.S. patent application Ser. No.11/167,390, filed Jun. 27, 2005, which claims priority under 35 U.S.C. §119e of U.S. provisional application Ser. No. 60/584,214 filed Jun. 30,2004.

FIELD OF THE INVENTION

The present invention relates to skin care cosmetic compositions andmethods. In particular, the present invention relates to novel cosmeticcompositions and methods comprising Rhodiola rosea extracts.

BACKGROUND OF THE INVENTION

Numerous attempts have been made to reduce the detrimental effects of UVradiation on the skin. In fact, UV exposure to skin is believed to causephotoaging, a term used to describe the changes in appearance and/orfunction of human skin as a result of repeated exposure to sunlight. Ofparticular concern are wrinkles, coarseness, mottled pigmentation,sallowness, and related changes in the appearance of skin as a result ofUV exposure.

Sunscreens are commonly used to prevent photoaging of skin areas thatare exposed to sunlight. Sunscreens are topical preparations thatcontain ingredients that absorb, reflect and/or scatter UV light. Somesunscreens are based on opaque particulate materials including zincoxide, titanium oxide, clays, and ferric chloride. However, because suchpreparations are visible and occlusive, many people consider thoseopaque formulations to be cosmetically unacceptable. Other sunscreenscontain chemicals such as p-aminobenzoic acid (PABA), oxybenzone,dioxybenzone, ethylhexyl-methoxy cinnamate, octocrylene, octylmethoxycinnamate, and butylmethoxydibenzoylmethane that are transparentor translucent on the skin. While these types of sunscreens may be moreacceptable cosmetically, they are still relatively short-lived andsusceptible to being removed by washing or perspiration. Moreover, thereis a continuing trend in the art to provide naturally-derived skin careingredients for application to the skin.

Therefore, there still remains a need for a novel composition and methodfor protecting the skin from UV-induced damage.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 provides a graphical depiction of the effect of Rhodiola rosea onsunburn cells.

FIG. 2 provides a graphical depiction of the effect of actives ofRhodiola rosea on DNA repair/damage.

SUMMARY OF THE INVENTION

The present invention comprises a cosmetic composition comprising aUV-protective amount of at least one rosavin. In a preferred embodiment,the rosavin is present in a plant extract. In one embodiment, theextract is an extract of Rhodiola rosea in a cosmetically acceptablevehicle.

The present invention further comprises a method of preventing orreducing the signs of photoaging comprising applying a compositioncomprising a UV-protective amount of at least one rosavin. In oneembodiment, the rosavin is contained in an extract of Rhodiola rosea anda cosmetically acceptable vehicle.

DETAILED DESCRIPTION

Except in operating and comparative examples, or where otherwiseexplicitly indicated, all numbers in this description indicating amountsor ratios of material or conditions of reaction, physical properties ofmaterials and/or use are to be understood as modified by the word“about.” All amounts are by weight of the final composition, unlessotherwise specified. By “effective amount” is meant an amount sufficientto cause a reduction in the effects of UV-damage.

The present invention is predicated on the observation that certainRhodiola rosea extracts have the surprising ability to protect skincells against the damaging effects of UV radiation. In further studies,it was eventually found that specific phenylpropanoids, in the extracts,collectively known as rosavins, are a principle protective component ofthe extract. Rosavins are components specific to Rhodiola rosea. Whilecomponents of Rhodiola rosea have been identified as having varioustypes of biological activity (Gregory S. Kelly, ND, “Rhodiola rosea: APossible Plant Adaptogen,” Alternative Medicine Review, Thorne Research,Inc., 2001), it was unexpected that the rosavins are primarilyresponsible for the UV-protective properties of Rhodiola rosea extracts.

As a background, the genus Rhodiola comprises several species of plantsin the Crassulacea family and is generally found in the arctic mountainregions of Siberia. The root of the plant is used medicinally and isalso known as “Arctic root” or “Golden root” and more recently as“Crenulin.” Rhodiola has been used for hundreds of years to treat coldand flu-like symptoms, promote longevity and increase the body'sresistance to physical and mental stresses. There are approximately 200species of the genus Rhodiola, and the phytochemistry andpharmacological properties of these plants may depend upon which speciesis being used (Komarov, 1939; Saratikov 1974; Kurkin and Zapesochnaya1986).

The species Rhodiola rosea grows primarily in dry, sandy ground at highaltitudes in the arctic areas of Europe and Asia. For centuries,Rhodiola rosea has been used in the traditional medicine of Russia,Scandinavia, and other countries. Recently, Rhodiola rosea has gainedpopularity as an oral supplement as an adaptogen. Adaptogens arereported to significantly accelerate the recovery process after illness,increase availability of energy, aid in reducing stress, increaseendurance and generate greater mental alertness.

The chemical composition of Rhodiola Rosea is well documented. Principalconstituents in R. rosea are cinnamyl alcohol vicyanoside rosavin,rosin, rosarin, (collectively the rosavins) andhydroxyphenylethanol-2-D-glucopyranoside (salidroside, also known asrhodioloside) (Saratikov et al. 1968; Kurkin and Zapesochnaya 1986 a,b).The presence of rosavins in Rhodiola seems to be specific to R. roseaonly (Kurkin and Zapesochnaya, 1996 a,b; Dubichev et al. 1991), whilethe presence of salidroside was shown in all plant species of the genusRhodiola (Bamaulov et al. 1965; Wang et al. 1992 a,b; Kang et al. 1992;Yoshikawa et al. 1996; Linh et al. 2000). For example, R. crenulata is amedicinal plant in Uzbekistan, China and other Asian countries with thesalidroside believed to be the active ingredient (Wang et al. 1992 b;Cui S et al. 2003). See also U.S. Publication No. 20020127285 (usesRhodiola crenulata, for its salidroside content at 0.5-10%).

Products incorporating Rhodiola rosea exist in the market, claiming adramatic effect on people due to its origin and the proprietary processin which it is manufactured. This is very important because the correctproportions of phytonutrients such as rosavin, rosin, rosarin andsalidroside, unless controlled, alter with the season and when consumedcan change the entire response to the body. As an example, the product,Rosavin™ (Siberian Rhodiola rosea), processed by Dr. Zakir Ramanzanov'sproprietary process is marketed for oral intake for various medicinalbenefits. Some claiming to be Rhodiola rosea contain very little rosavinand high amounts of heavy metals and still others do not containrosavin, rosarin or rosin at all.

Rhodiola extracts or concentrates of the effective ingredients ofRhodiola, are obtained by contacting the plant part with a suitablesolvent, such as water, alcohol, methanol, or any other solvents, ormixed solvents. The choice of the solvent may be made routinely, e.g.,based on the properties of the active ingredient that is to be extractedor concentrated by the solvent. Preferred active ingredients of Rhodiolarosea include but are not limited to, rosavins, salidroside and tyrosol.These ingredients can be extracted in the same step, e.g., using analcoholic or water solvent, or they may be extracted individually, eachtime using a solvent which is especially effective for extracting theparticular target ingredient from the plant.

In initial experiments, it has been surprisingly discovered in thepresent invention that an extract of Rhodiola rosea effectively protectsthe skin from photodamage. Specifically, while not wishing to be boundby any theory, it is believed that specific extracts of Rhodiola roseaincrease DNA repair and therefore protect against UV-induced skindamage.

Rhodiola rosea is believed to have six distinct groups of chemicalcompounds: phenylpropanoids including rosavins, rosin and rosarin;phenylethanol derivatives including salidroside (rhodioloside) andtyrosol; flavonoids including rodiolin, rodionin, rodiosin,acetylrodalgin and tricin; monoterpenes including rosiridol androsaridin; triterpenes including daucosterol and beta-sitosterol; andphenolic acids including chlorogenic and hydroxycinnamic and gallicacids. See “Rhodiola Rosea A Phytomedical Overview,” HerbalGram, RichardP. Brown et al., 2002.

As subsequent experiments show (see Example 2) the rosavins are aprimary active component in Rhodiola extracts. Rosavins are relativelyeasily isolated from plant material containing them by known chemicaltechniques. Effective amounts of isolated rosavins, i.e., any one or acombination of rosavins, can therefore be used in a topical compositionto achieve the UV-protective effect. The effective amount of isolatedrosavin incorporated into a composition will ordinarily be in the rangeof from 0.0001% to 0.1%, preferably from 0.001% to 0.008% and mostpreferably 0.004% by weight of the total composition. However, as apractical matter, it is also possible, and perhaps more convenient, toinclude a rosavin-containing compound in the composition to achieve aprotective rosavin effect. In a preferred embodiment, an extract of anyplant containing rosavins is appropriate for use in the compositions ormethods of the invention. However, Rhodiola rosea extracts containingrosavins are available from a wide range of commercial sources (AmaxNutraSource Inc., Eugene, Oreg.; Solgar Vitamin and Herb, Leonia, N.J.;Jarrow Formulas, Inc., Los Angeles, Calif.), and thus most convenient.

Concentrations of the active rosavins may vary from extract to extract,so as a guideline, it is recommended to use the amount of extract thatwould provide an equivalent concentration of isolated rosavin as notedabove. In addition, as shown in the examples below, although rosavinsare the principle active component in achieving UV-protection,additional components, although not necessarily very effective on theirown, may be present in the plant extracts that can have somecontributory activity. In one preferred embodiment, the extract ofRhodiola rosea contains a combination of rosavins and salidrosides. Therosavins are present in an amount of from 1% to 50%, preferably from 2%to 40%, and most preferably from 4% to 5% of the extract. Thesalidrosides are present in an amount from 0.1% to 50%, preferably from0.5% to 40%, and most preferably from 1% to 5% of the composition andfrom 0.0001% to 30%, preferably from 0.001% to 20% and most preferablyfrom 0.01% to 10% of the extract. The preferred Rhodiola rosea extractis commercially available from Amax Nutrasource Inc. in Eugene, Oreg.

The amount of extract will vary depending on the formulation and theperformance desired, and also on the concentration of the rosavins inthe extract, as noted above. A typical Rhodiola rosea extract, e.g., onecontaining from 0.0001% to 0.1% of rosavins, is used in an amount from0.0001% to 90% by weight of the composition is used. Preferably,Rhodiola rosea is used in an amount from 0.001% to 70%, and mostpreferably, from 0.1% to 10%.

In an alternate embodiment, the present invention includes a sunscreen.Suitable sunscreens include water soluble sunscreens (such as Eusolex232); oil soluble sunscreens (such as octyl methoxycinnamate); inorganicsunscreens (such as titanium dioxide, zinc oxide) and organic sunscreens(such as camphor derivatives, cinnamates, salicylates, benzophenones,triazines, PABA derivatives, diphenylacrylate derivatives, anddibenzoylmethane derivatives.)

The amount will vary depending on the formulation and the performancedesired. The sunscreen is used in an amount from 0.1% to 50% by weightof the composition. Preferably, the sunscreen is used in an amount from1% to 40% and most preferably, an amount of from 5% to 30%.

The composition further comprises a cosmetically acceptable vehicle thatis suitable for topical application to skin, hair and/or nails.Cosmetically acceptable vehicles are well known in the art and areselected based on the end use of the application. For example, vehiclesof the present invention include, but are not limited to, those suitablefor application to the skin. Such vehicles are well known to those ofordinary skill in the art, and can include one or more compatible liquidor solid filler diluents or vehicles which are suitable for applicationto the skin. The exact amount of vehicle will depend upon the level ofany other optional ingredients that one of ordinary skill in the artwould classify as distinct from the vehicle (e.g., other activecomponents). The compositions of the present invention preferablycomprise from about 75% to about 99.99%, more preferably from about 85%to about 99.99%, and most preferably from about 93% to about 98%, byweight of the composition, of a vehicle.

The vehicle and the compositions herein can be formulated in a number ofways, including but not limited to emulsions. For example, suitableemulsions include oil-in-water, water-in-oil, water-in-oil-in-water,oil-in-water-in-oil, and oil-in-water-in-silicone emulsions. Preferredcompositions comprise an oil-in-water emulsion.

The compositions of the present invention can be formulated into a widevariety of product types, including shampoos, creams, waxes, pastes,lotions, milks, mousses, gels, oils, tonics and sprays. Preferredcompositions are formulated into lotions, creams, gels, shampoos andsprays. These product forms may be used for a number of applications,including but not limited to, hand and body lotions, cold creams, facialmoisturizers, anti-acne preparations, topical analgesics,make-ups/cosmetics including foundations, eyeshadows, lipsticks and thelike. Any additional components required to formulate such products varywith product type and can be routinely chosen by one skilled in the art.

If compositions of the present invention are formulated as an aerosoland applied to the skin as a spray-on product, a propellant may be addedto the composition. Examples of suitable propellants includechlorofluorinated lower molecular weight hydrocarbons. A more completedisclosure of propellants useful herein can be found in Sagarin,Cosmetics Science and Technology, 2^(nd) Edition, Vol. 2, pp. 443-465(1972).

Other Components

The formulation also can comprise other components that may be chosendepending on the carrier and/or the intended use of the formulation.Additional components include, but are not limited to antioxidants (suchas BHT); chelating agents (such as disodium EDTA); emulsion stabilizers(such as carbomer); preservatives (such as methyl paraben); fragrances(such as pinene); flavoring agents (such as sorbitol); humectants (suchas glycerine); waterproofing agents (such as PVP/Eicosene copolymer);water soluble film-formers (such as hydroxypropyl methylcellulose);oil-soluble film formers (such as hydrogenated C-9 Resin); moisturizingagents, such as cholesterol; cationic polymers (such as Polyquatenium10); anionic polymers (such as xanthan gum); vitamins (such astocopherol); and the like.

The compositions can also encompass one or more additional activecomponents, and as such can be either cosmetic or pharmaceuticalcompositions. Examples of useful actives include, but are not limitedto, those that improve or eradicate age spots, keratoses and wrinkles,analgesics, anesthetics, anti-acne agents, antibacterials, antiyeastagents, antifungal agents, antiviral agents, antidandruff agents,antidermatitis agents, antipruritic agents, antiemetics,antihyperkeratolytic agents, anti-dry skin agents, antiperspirants,antipsoriatic agents, antiseborrheic agents, hair conditioners and hairtreatment agents, antiaging agents, antiwrinkle agents, antiasthmaticagents and bronchodilators, sunscreen agents, antihistamine agents,depigmenting agents, wound-healing agents, vitamins, corticosteroids,tanning agents or hormones. More specific examples of useful activeagents include retinoids such as retinol, and esters, acids, andaldehydes thereof, ascorbic acid, and esters and metal salts thereof,tocopherol and esters and amide derivatives thereof, shark cartilage;milk proteins; alpha- or beta-hydroxy acids; DHEA and derivativesthereof, topical cardiovascular agents; clotrimazole, ketoconazole,miconozole, griseofulvin, hydroxyzine, diphenhydramine, pramoxine,lidocaine, procaine, mepivacaine, monobenzone, erythromycin,tetracycline, clindamycin, meclocyline, hydroquinone, minocycline,naproxen, ibuprofen, theophylline, cromolyn, albuterol, hydrocortisone,hydrocortisone 21-acetate, hydrocortisone 17-valerate, hydrocortisone17-butyrate, betamethasone valerate, betamethasone diproprionate,triaminolone acetonide, fluocinonide, clobetasol, proprionate, benzoylperoxide, crotamiton, propranol, promethazine, and mixtures thereof.

Particularly preferred embodiments of the present formulations are skincare lotions or creams used as an anti-aging product. To that end, thepresent formulations are combined with agents that are moisturizers,emollients or humectants. Examples of useful combinations are oils,fats, waxes, esters, fatty acid alcohols, fatty acid ethoxylates,glycols, sugars, hyaluronic acid and hyaluronates, dimethicone,cyclomethicone, and the like. Further examples can be found in theInternational Cosmetic Ingredient Dictionary, CTFA, Sixth Edition, 1995.

Method of Reducing the Signs of Photoaging

The present inventive compositions are particularly useful as productsas methods of retarding the signs of photoaging and protecting the skinfrom UV damage. As used herein, “photoaging” can include signs of agingsuch as skin atrophy and means the thinning and/or general degradationof the dermis caused by free radical damage which is often characterizedby an alteration and degeneration of collagen and/or elastin due toextrinsic factors such as photodamage caused by exposure to UVradiation. As used herein, “retarding the signs of photoaging” includesarresting, treating, or reversing the process of skin aging in mammalianskin. Examples of retarding skin aging include but is not limited toreduction of the appearance of lines and wrinkles, reduction of theeffect of skin atrophy and reduction of the appearance of thinning.

Such methods comprise administering or topically applying to the skin asafe and effective amount of the composition of the present invention.The amounts of the components in the compositions will vary widelydepending upon the level of regulation desired.

A preferred method of cosmetically or pharmaceutically treating the skinis via chronic topical application of a safe and effective amount of thenovel composition to protect the skin. The amount of the composition andthe frequency of topical application to the skin can vary widely,depending upon the individual's desired amount of protection for totalcoverage or on an as-needed basis. It is well within the purview of theskilled artisan, such as a dermatologist or other health care provider,to regulate pharmaceutical dosages according to patient needs. Themethod of the present invention is suitable for daily use.

It is suggested as an example that topical application range from aboutonce per week to about 2 or 3 times daily, preferably from about 5 timesa week to about 3 times daily, most preferably about once or twice perday. The compositions will comprise from 0.0001% to 0.5%, preferablyfrom 0.001% to 0.01% and most preferably 0.002% 0.009% of the activecomponents.

The following examples further illustrate the invention, but theinvention is not limited thereto.

EXAMPLE 1

The following are two compositions within the scope of the presentinvention.

Composition A TRADE NAME CTFA NAME PERCENT Lipocol C/Cetyl Alcohol NFCetyl Alcohol 1.65 Glyceryl Monostearate Pure Glyceryl Stearate 1.65Arlacel 165 Glyceryl Stearate/PEG-100 Stearate 6.60 Lanette O CetearylAlcohol 1.10 Softisan 378 Caprylic/Capric/Myrstic/Stearic Triglyceride0.50 Silicone 200 (100 CTS.) Dimethicone 0.40 Cetiol LCCoco-Caprylate/Caprate 3.60 Tween 40 Polysorbate 40 0.66 Span 40Sorbitan Palmitate 0.44 Wickenol 161 Dioctyl Adipate/OctylStearate/Octyl Palmitate 3.30 Deionized Water Purified Water 74.0 1,3Butylene Glycol Butylene Glycol 6.00 Rhodiola Rosea 4% Rhodiola RoseaRoot Extract 0.10

Composition B TRADE NAME CTFA NAME PERCENT Satin Finish III-9Water/Phenyl Trimethicone/Cyclomethicone/ 50.0Dimethiconol/Phosphoglycerides/Carbomer/ Triethanolamine Tristrat SDHASodium Dehydroacetate 0.10 Disodium EDTA/Trilon Disodium EDTA 0.14 BDGlycerine USP 99% Glycerin 3.00 (Vegetable) Dry Flo Pure 28-1850/DryAluminum Starch Octenylsuccinate 1.00 Flow Plus Deionized Water PurifiedWater 41.71 Carbopol 1382 Acrylates/C10-30 Alkyl Acrylate Crosspolymer0.30 Carbopol 980 Carbomer 0.35 Glycerine USP 99% Glycerin 1.00(Vegetable) Keltrol T Xanthan Gum 0.20 Deionized Water Purified Water2.00 Triethanolamine 99% Triethanolamine 0.10 Rhodiola Rosea 4% RhodiolaRosea Root Extract 0.10

EXAMPLE 1

The effect of Rhodiola rosea on UVB-induced sunburn cell formation inliving skin equivalents (LSEs) is tested. Excised portions (8 mm) aretaken from living skin equivalents (Organogenesis) and cultured overtranswell membrane plates. These excised portions are pre-treated withRhodiola rosea at 0.1 mg/ml (PBS) for 4 hours. After thepost-incubation, these excised portions are UVB-irradiated at 0, 50,100, 150 and 200 mJ/cm². Following a 24 hour post-incubation, these skinequivalents are fixed in formalin and stored at −4° C. These samples arethen stained using H&E staining. Sections are then evaluated using amicroscope at 400× magnification. A section is selected from each sampleand counts of sunburn cells were made.

Results and Discussion: As seen in FIG. 1, UVB induces a dose-dependentincrease of sunburn cell formation in living skin equivalents. There are10, 21 and 32 sunburn cells in a selected field at 100 mJ, 150 mJ, and200 mJ UVB radiation, respectively (FIGS. 1& 2 left side). In the LSEspre-treated with rhodiola rosea, there are 2, 10, and 14 sunburn cellsin a selected field at 100 mJ, 150 mJ, and 200 mJ UVB radiation,respectively. Pre-treatment with Rhodiola rosea significantly reducesthe formation of sunburn cells via UVB irradiation. Rhodiola roseapre-treatment is found to significantly reduce UVB induced sunburn cellformation in LSE.

EXAMPLE 2

Excised portions (8 mm) are taken from living skin equivalents (LSE) andcultured over transwell membrane plates. These excised portions arepre-treated with rosavin or salidroside at 0.01% (PBS) for 18 hours.After the post-incubation, these excised portions are UVB-irradiated at0 and 175 mJ/cm². One set of LSEs is immediately fixed in formalin todetermine TT dimer formation (DNA damage). Following a 24-hourpost-incubation, another set of skin equivalents is fixed in formalin.These samples are then prepared for TT dimer immunostaining. Sectionsare then evaluated using a microscope at 400× magnification. A sectionis selected from each sample and TT dimer containing cells areevaluated. DNA damage is measured by examining TT dimer stained cellsimmediately after UVB irradiation. DNA repair (TT dimer removal) inUVB-irradiated LSEs is determined by comparing the levels of TT dimer at0 hr (immediately after UVB) with the levels of TT dimer at 24 hours (24hours after UVB). Results & Discussion: As seen in FIG. 2, UVB inducesan increase in DNA damage cells (TT dimer stained) in living skinequivalents with or without rosavin or salidroside pre-treatment. In thecontrol, TT dimer levels in LSE are found to be at 40%, 24 hours after175 mJ of UVB. In rosavin-treated LSE, TT dimer levels are at 7%, 24hours after 175 mJ of UVB. In salidroside-treated LSE, TT dimer levelsare at 12%, 24 hours after 175 mJ of UVB. Twenty-four hours later, thereis a significant reduction in DNA damaged cells in the LSE. Inconclusion, the results of the experiment demonstrate that rosavin maybe the active component in Rhodiola rosea in providing the protectiveeffects observed from Rhodiola rosea.

It should be understood that the specific forms of the invention hereinillustrated and described are intended to be representative only.Changes, including but not limited to those suggested in thisspecification, may be made in the illustrated embodiments withoutdeparting from the clear teachings of the disclosure. Accordingly,reference should be made to the following appended claims in determiningthe full scope of the invention.

1. An aqueous based cosmetic composition comprising an effective amountof: an extract of Rhodiola Rosea; and a mixture of glycerin and butyleneglycol.
 2. The composition of claim 1 wherein the Rhodiola Roseacontains from about 0.001% to 0.1% by weight rosavins.
 3. The cosmeticcomposition of claim 1 wherein the Rhodiola Rosea comprises asalidrosides, rosavins, rosins, rosarins, or mixtures thereof.
 4. Thecosmetic composition of claim 1 further comprising at least from 0.001%to 0.1% of tyrosol.
 5. The cosmetic composition of claim 1 which is agel.
 6. The composition of claim 1 which is a facial moisturizer.
 7. Thecomposition of claim 1 further comprising at least one chelating agent.8. The composition of claim 7 wherein the chelating agent is disodiumEDTA.
 9. The composition of claim 1 further comprising a sugar.
 10. Thecomposition of claim 9 further comprising hyaluronic acid, ahyaluronate, or mixtures thereof.
 11. An aqueous based cosmeticcomposition comprising: an extract of Rhodiola Rosea; and at least oneof hyaluronic acid, a hyaluronate, or mixtures thereof.
 12. Thecomposition of claim 11 wherein the hyaluronate is sodium hyaluronate.13. The composition of claim 11 which is a gel.
 14. The composition ofclaim 11 which is a facial moisturizer.
 15. An aqueous based facialmoisturizer comprising an effective amount of an extract of RhodiolaRosea; and at least one chelating agent, at least one emulsionstabilizer, at least one fragrance, at least one humectant, at least oneglycol, and at least one protein.
 16. The composition of claim 15wherein the chelating agent is disodium EDTA.
 17. The composition ofclaim 15 wherein the at least one humectant comprises glycerin.
 18. Thecomposition of claim 15 wherein the at least one glycol comprisesbutylene glycol.
 19. The composition of claim 15 further comprising atleast one sugar.
 20. The composition of claim 15 in gel form.